Indefinite Delivery Contract SPE2DB25D9240

The federal contract IDV award SPE2DB25D9240 is a single-award Indefinite Delivery Contract (IDC) valued at up to $499,999,999, issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has an ultimate completion date of November 30, 2026 and covers the provision of a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military health facilities worldwide.

The IDC allows DLA to issue firm fixed-price delivery orders for a vast array of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. Key products supplied by DMS Pharmaceutical Group include flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications, as well as common antibiotics, pain relievers, and cardiovascular drugs. This IDC complements the company's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense (DoD) healthcare facilities, solidifying its position as a critical supplier in the federal pharmaceutical supply chain.